Does the current apixaban dosing strategy adequately fit and ensure safety in Korean patients with atrial fibrillation?
作者信息
Kim Bohyun
机构信息
Department of Laboratory Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
出版信息
Blood Res. 2025 Sep 8;60(1):50. doi: 10.1007/s44313-025-00103-4.
Abstract
摘要
相似文献
1
Does the current apixaban dosing strategy adequately fit and ensure safety in Korean patients with atrial fibrillation?目前的阿哌沙班给药策略是否适合韩国房颤患者并确保其安全性？
Blood Res. 2025 Sep 8;60(1):50. doi: 10.1007/s44313-025-00103-4.
2
Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results.具有单剂量减量标准的房颤患者应用阿哌沙班的结果：ASPIRE研究1年结果
Eur Heart J Cardiovasc Pharmacother. 2025 Aug 12;11(5):403-411. doi: 10.1093/ehjcvp/pvaf018.
3
Effectiveness and Safety of Edoxaban Compared With Apixaban in Elderly Patients With Nonvalvular Atrial Fibrillation: A Real-World Population-Based Cohort Study.依度沙班与阿哌沙班治疗老年非瓣膜性心房颤动患者的有效性和安全性：一项基于真实世界人群的队列研究。
Stroke. 2024 May;55(5):1161-1170. doi: 10.1161/STROKEAHA.123.045098. Epub 2024 Mar 21.
4
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.阿哌沙班预防非瓣膜性心房颤动的卒中。
N Engl J Med. 2024 Jan 11;390(2):107-117. doi: 10.1056/NEJMoa2310234. Epub 2023 Nov 12.
5
Real-world apixaban concentration in Korean patients with atrial fibrillation.韩国房颤患者的真实世界阿哌沙班血药浓度
Blood Res. 2025 Jul 7;60(1):39. doi: 10.1007/s44313-025-00089-z.
6
Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.真实世界中阿哌沙班在房颤卒中预防中的应用：系统评价和荟萃分析。
Stroke. 2018 Jan;49(1):98-106. doi: 10.1161/STROKEAHA.117.018395. Epub 2017 Nov 22.
7
Population Pharmacokinetic Modelling of Apixaban in End-Stage Kidney Disease Patients with Atrial Fibrillation Receiving Haemodialysis.接受血液透析的终末期肾病合并心房颤动患者中阿哌沙班的群体药代动力学建模
Clin Pharmacokinet. 2025 Feb;64(2):307-321. doi: 10.1007/s40262-025-01476-6. Epub 2025 Jan 24.
8
Effectiveness and Safety of Dose-Specific DOACs in Patients With Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.特定剂量直接口服抗凝剂在房颤患者中的有效性和安全性：一项系统评价与网状Meta分析
Cardiovasc Ther. 2025 Jan 6;2025:9923772. doi: 10.1155/cdr/9923772. eCollection 2025.
9
Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.非维生素K口服抗凝药用于非瓣膜性心房颤动的相对疗效和安全性：在三个患者亚组中比较阿哌沙班、达比加群、利伐沙班和依度沙班的网状Meta分析
Int J Cardiol. 2016 Feb 1;204:88-94. doi: 10.1016/j.ijcard.2015.11.084. Epub 2015 Nov 17.
10
Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial.根据既往口服抗凝药使用情况，比较阿孙地昔或阿哌沙班用于房颤患者：OCEANIC-AF随机临床试验的亚组分析
JAMA Cardiol. 2025 Mar 26. doi: 10.1001/jamacardio.2025.0277.
本文引用的文献
1
Real-world apixaban concentration in Korean patients with atrial fibrillation.韩国房颤患者的真实世界阿哌沙班血药浓度
Blood Res. 2025 Jul 7;60(1):39. doi: 10.1007/s44313-025-00089-z.
2
Back to basics: the coagulation pathway.回归基础：凝血途径。
Blood Res. 2024 Oct 28;59(1):35. doi: 10.1007/s44313-024-00040-8.
3
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2023 ACC/AHA/ACCP/HRS 指南：心房颤动的诊断与管理——美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
Circulation. 2024 Jan 2;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193. Epub 2023 Nov 30.
4
The relationship between DOAC levels and clinical outcomes: The measures tell the tale.直接口服抗凝剂（DOAC）水平与临床结局之间的关系：这些指标说明了情况。
J Thromb Haemost. 2020 Dec;18(12):3163-3168. doi: 10.1111/jth.15104. Epub 2020 Oct 19.
5
Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial.阿哌沙班校准的抗Xa因子活性与房颤患者结局事件及临床特征的关系：AVERROES试验结果
TH Open. 2017 Dec 12;1(2):e139-e145. doi: 10.1055/s-0037-1613679. eCollection 2017 Jul.
6
Global rising trends of atrial fibrillation: a major public health concern.心房颤动的全球上升趋势：一个重大的公共卫生问题。
Heart. 2018 Dec;104(24):1989-1990. doi: 10.1136/heartjnl-2018-313350. Epub 2018 Jun 15.
7
Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study.重新审视非瓣膜性心房颤动结局中的性别差异：一项基于人群的队列研究。
Eur Heart J. 2017 May 14;38(19):1473-1479. doi: 10.1093/eurheartj/ehw613.
8
Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.实验室检测评估阿哌沙班血药浓度：三种抗 Xa 检测方法的适用性。一项多中心法国 GEHT 研究。
Thromb Haemost. 2014 Feb;111(2):240-8. doi: 10.1160/TH13-06-0470. Epub 2013 Oct 31.
9
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.健康受试者多次口服Xa因子抑制剂阿哌沙班的安全性、药代动力学和药效学
Br J Clin Pharmacol. 2013 Nov;76(5):776-86. doi: 10.1111/bcp.12106.
Zotero 插件